Table 2 Baseline information and clinical characteristics of SMH patients

Age, years (mean ± SD)

62.06 ± 17.73

Sex (male), n (%)

11 (61.11%)

Primary disease, eyes (%)

 PCV

10 (55.56%)

 nAMD

1 (5.56%)

 RAM

5 (27.78%)

 Traumatic retinopathy

2 (11.11%)

Preoperative BCVA, logMAR (mean ± SD)

1.85 ± 0.62

Foveal involvement, eyes (%)

18 (100.00%)

GLD of SMH, μm (mean ± SD)

6538.17 ± 2533.11

Height of SMH, μm (mean ± SD)

937.36 ± 420.21

Comorbidity, eyes (%)

 Cataract

12 (66.67%)

 Pseudophakia

2 (11.11%)

 VH

8 (44.44%)

 RD

1 (5.56%)

 Hemorrhagic PED

2 (11.11%)

Interval from disease onset to surgery, days (mean ± SD)

38.28 ± 44.40

Surgery details

 Duration of ILM peeling, min (mean ± SD)

5.54 ± 3.39

 Duration of rt-PA injection, min (mean ± SD)

3.14 ± 1.25

 C3F8 tamponade, eyes (%)

17 (94.44%)

 Silicone oil tamponade, eyes (%)

1 (5.56%)

 Combined with cataract surgery, eyes (%)

8 (44.44%)

 Combined with anti-VEGF treatment, eyes (%)

4 (22.22%)

 Intraoperative iatrogenic retinal breaks, eyes (%)

0 (0%)

Postoperative ocular status, eyes (%)

 With complications requiring additional surgery

4 (22.22%)

 SMH complete absorption

9 (50.00%)

 SMH partial absorption

6 (33.33%)

 No absorption

1 (5.56%)

Total number of additional PPV, n (%)

4 (22.22%)

Final BCVA, logMAR (mean ± SD)

1.14 ± 0.82^*

Postoperative visual prognosis, eyes (%)

 Improved

14 (77.78%)

 Stable

3 (16.67%)

 Worsened

1 (5.56%)

Complications, eyes (%)

 Recurrent SMH or VH

2 (11.11%)

 RD

2 (11.11%)

 Endophthalmitis

0 (0.00%)

Follow-up period, days (mean ± SD)

122.17 ± 48.83